These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 14985771)

  • 1. Scientists and societies. The Polish biotech gap.
    Gorlach S; Slabicki M
    Nature; 2004 Feb; 427(6977):870. PubMed ID: 14985771
    [No Abstract]   [Full Text] [Related]  

  • 2. State of the biotech sector - 2006.
    Lawrence S
    Nat Biotechnol; 2007 Jul; 25(7):706. PubMed ID: 17621283
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotech holds its own in Q2.
    Lawrence S
    Nat Biotechnol; 2004 Aug; 22(8):938. PubMed ID: 15286634
    [No Abstract]   [Full Text] [Related]  

  • 4. Hedge funds gain edge by doubling biotech investments.
    Ransom J
    Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
    [No Abstract]   [Full Text] [Related]  

  • 5. US government previews biotech survey.
    Goho A
    Nat Biotechnol; 2003 Aug; 21(8):837-8. PubMed ID: 12894185
    [No Abstract]   [Full Text] [Related]  

  • 6. Hwang scandal hits Korean biotech hard.
    Fuyuno I
    Nature; 2006 Jan; 439(7074):265. PubMed ID: 16421542
    [No Abstract]   [Full Text] [Related]  

  • 7. John McCamant on the future of biotech. Interview by Dennis Murray.
    McCamant J
    Med Econ; 2002 Jan; 79(1):43-6. PubMed ID: 11807995
    [No Abstract]   [Full Text] [Related]  

  • 8. Crystal gazing: biotech's financial outlook: the biotech analyst's view.
    Schmidt E
    Nat Biotechnol; 2006 Mar; 24(3):261-2. PubMed ID: 16525376
    [No Abstract]   [Full Text] [Related]  

  • 9. White biotech and the financial crisis.
    Rabinovich M
    Biotechnol J; 2009 Aug; 4(8):1117-23. PubMed ID: 19685465
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotech slumps in Q1.
    Lawrence S
    Nat Biotechnol; 2008 May; 26(5):486. PubMed ID: 18464769
    [No Abstract]   [Full Text] [Related]  

  • 11. Australian biotech suffers growing pains.
    O'Neill G
    Nat Biotechnol; 2005 Apr; 23(4):401-2. PubMed ID: 15815652
    [No Abstract]   [Full Text] [Related]  

  • 12. Icelandic biotech feels the pinch.
    Wadman M
    Nature; 2008 Oct; 455(7215):842. PubMed ID: 18938257
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of private financing hobbles emerging biotech regions.
    Jia H; Jayarama KS; Astvatsaturyan M
    Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
    [No Abstract]   [Full Text] [Related]  

  • 14. Back to life.
    Smaglik P
    Nature; 2004 May; 429(6990):483. PubMed ID: 15164076
    [No Abstract]   [Full Text] [Related]  

  • 15. Biotech financing retrenches in Q2.
    Lawrence S
    Nat Biotechnol; 2006 Aug; 24(8):883. PubMed ID: 16900116
    [No Abstract]   [Full Text] [Related]  

  • 16. Could bank loans solve Europe's biotech financing slump?
    Mitchell P
    Nat Biotechnol; 2005 Dec; 23(12):1459-60. PubMed ID: 16333276
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotech business Down Under.
    Beckley C
    Nature; 2004 Jun; 429(6991 Suppl):5-9. PubMed ID: 15175704
    [No Abstract]   [Full Text] [Related]  

  • 19. Little biotech on the prairie.
    Wolfson W
    Chem Biol; 2007 Sep; 14(9):969-71. PubMed ID: 17884626
    [No Abstract]   [Full Text] [Related]  

  • 20. White biotechnology: ready to partner and invest in.
    Kircher M
    Biotechnol J; 2006; 1(7-8):787-94. PubMed ID: 16897821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.